Acebutolol, a Cardioselective Beta Blocker, Promotes Glucose Uptake in Diabetic Model Cells by Inhibiting JNK-JIP1 Interaction.
10.4062/biomolther.2017.123
- Author:
Yi LI
1
;
Nan Young JUNG
;
Jae Cheal YOO
;
Yul KIM
;
Gwan Su YI
Author Information
1. Department of Bio and Brain Engineering, KAIST, Daejeon 34141, Republic of Korea. gsyi@kaist.ac.kr
- Publication Type:Original Article
- Keywords:
Acebutolol;
JNK inhibitor;
Glucose uptake;
Drug screening;
Diabetes Mellitus
- MeSH:
Acebutolol*;
Adipocytes;
Cell Communication;
Diabetes Mellitus;
Drug Evaluation, Preclinical;
Glucose*;
Hypertension;
Insulin;
Insulin Resistance;
Liver;
Methods;
Phosphorylation
- From:Biomolecules & Therapeutics
2018;26(5):458-463
- CountryRepublic of Korea
- Language:English
-
Abstract:
The phosphorylation of JNK is known to induce insulin resistance in insulin target tissues. The inhibition of JNK-JIP1 interaction, which interferes JNK phosphorylation, becomes a potential target for drug development of type 2 diabetes. To discover the inhibitors of JNK-JIP1 interaction, we screened out 30 candidates from 4320 compound library with In Cell Interaction Trap method. The candidates were further confirmed and narrowed down to five compounds using the FRET method in a model cell. Among those five compounds, Acebutolol showed notable inhibition of JNK phosphorylation and elevation of glucose uptake in diabetic models of adipocyte and liver cell. Structural computation showed that the binding affinity of Acebutolol on the JNK-JIP1 interaction site was comparable to the known inhibitor, BI-78D3. Our results suggest that Acebutolol, an FDA-approved beta blocker for hypertension therapy, could have a new repurposed effect on type 2 diabetes elevating glucose uptake process by inhibiting JNK-JIP1 interaction.
